
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics is viewed positively due to its strong pipeline of cell therapies that demonstrate the potential for significant levels of efficacy and safety in treating cancer and autoimmune disorders. The company's reliance on partners for access to gene-editing technology could pose risks, but the recent stock price decline presents an attractive entry point for investors, especially after the positive interim futility results from the ALPHA3 trial for cema-cel. Additionally, the high MRD-negativity rate observed in the trial could potentially lead to a new therapy benchmark for 1L DLBCL patients. However, the company will need additional funding to support the development and commercialization of its product candidates.
Bears say
Allogene Therapeutics is facing potential setbacks in its main product candidate cema-cel, with a bear case scenario lowering its probability of success to 5%. This results in a reduced fair value of $1, highlighting the high risk involved in investing in the company. Additionally, the company's DCF-based valuation methodology projects a total firm value of $3.76B, resulting in a price objective of $12 per share, with potential risks including durability challenges and manufacturing issues.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares